# Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration

> **NCT00457444** · PHASE1 · COMPLETED · sponsor: **University of Zurich** · enrollment: 35 (—)

## Conditions studied

- Rhinoconjunctivitis

## Interventions

- **DRUG:** Pollen

## Key facts

- **NCT ID:** NCT00457444
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 35 (—)
- **Last updated:** 2007-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00457444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00457444, "Study to Assess the Clinical Efficacy and Safety of a Novel Method of Specific Allergen Immunotherapy in Grass Pollen Allergic Subjects by Epicutanous Allergen Administration". Retrieved via MORVS 2026-10-22 from https://api.morvs.ai/clinical/NCT00457444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*